Evidence map›Paper›PMID 26867042›Full record

ArticleHealth psychology : official journal of the Division of Health Psychology, American Psychological Association2016

Affective forecasting and medication decision making in breast-cancer prevention.

Michael Hoerger, Laura D Scherer, Angela Fagerlin

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients.Medical decision making : an international journal of the Society for Medical Decision Making · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Michael HoergerDepartment of Psychology, Tulane Cancer Center.
Laura D SchererDepartment of Psychological Sciences, University of Missouri.
Angela FagerlinDepartment of Medicine, University of Michigan.
University of Michigan–Ann Arbor · USUniversity of Missouri · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Training / Career DevelopmentP50CA101451 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI STRECHER, VICTOR J · 2003 to 2012
$18.2M
NIMH INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDT32MH018911 · NIMH · UNIVERSITY OF ROCHESTER · PI CAINE, ERIC D. · 1988 to 2012
$2.9M
NCI NIH HHS P50 CA101451NIGMS NIH HHS U54 GM104940NIMH NIH HHS T32 MH018911
6 · The paper itself

Abstract

objectiveOver 2 million American women at elevated risk for breast cancer are eligible to take chemoprevention medications such as tamoxifen and raloxifene, which can cut in half the risk of developing breast cancer, but which also have a number of side effects. Historically, very few at-risk women have opted to use chemoprevention medications. Affective forecasting theory suggests that people may avoid these medications if they expect taking them to increase their health-related stress.

methodAfter receiving an individually tailored decision aid that provided personalized information about the risks and benefits of these medications, 661 women at elevated risk of breast cancer were asked to make 3 affective forecasts, predicting what their level of health-related stress would be if they took tamoxifen, raloxifene, or neither medication. They also completed measures of decisional preferences and intentions, and at a 3-month follow-up, reported on whether or not they had decided to use either medication.

resultsOn the affective forecasting items, very few women (<10%) expected the medications to reduce their health-related stress, relative to no medication at all. Participants with more negative affective forecasts about taking a chemoprevention medication expressed lower preferences and intentions for using the medications (Cohen's ds from 0.74 to 0.79) and were more likely to have opted against using medication at follow-up (OR range = 1.34-2.66).

conclusionThese findings suggest that affective forecasting may explain avoidance of breast-cancer chemoprevention medications. They also highlight the need for more research aimed at integrating emotional content into decision aids. (PsycINFO Database Record

Indexed as

Decision MakingAdultAgedAntineoplastic AgentsBreast NeoplasmsChemopreventionDecision Support TechniquesFemaleFollow-Up StudiesForecastingHumansIntentionMedication AdherenceMiddle AgedRaloxifene HydrochlorideRisk AssessmentAntineoplastic AgentsRaloxifene HydrochlorideTamoxifen

Identifiers

PMID26867042
PMCPMC4868645
OpenAlexW2407875281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.